References
- Greene MH, Clark JW, Blayney DW. Epidemiology of ovarian cancer. Semin Oncol 1984; 11: 209–226.
- McGuire WP, Hoskins W, Brady MF et al. Cyclofophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6.
- Bertelsen K, Kaenn J, Simonsen E et al. Is cisplatin-taxol the standard treatment in advanced ovarian cancer ? Eur J Cancer 1998; 33:614.
- Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with previously treated with cis-platin. J Clin Oncol 1991; 9: 389–393.
- Omura G, Brady MF, Homesley H et al. Long term fol-low up and prognostic factor analysis in advanced ovarian car-cinoma. The Gynecologic Oncology Group Experience. J Clin Oncol 1991; 9: 1138–1150.
- Surwit EA, Alberts D, O'Toole R et al. Phase II trial of vinorelbine in previously treated patients with ovarian cancer. A Southwest Oncology Group Study. Gynecol Oncol 1987; 27: 214–221.
- Ozols RF, Young RC. Ovarian cancer. Curr Probl Cancer 1987; 11: 59–122.
- Piccart MJ, Green JA, Lacavre AJ, et al. Oxaliplatin or paclitaxel in patients with platinum pretreated advanced ovari-an cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. L Clin Oncol 2000; 18: 1193–1202.
- Vermoken J, Gore M, Perren T, et al. Multicenter ran-domized phase II study of oxaliplatin or topotecan in platinum pretreated epithelial ovarian cancer patients. ASCO Proc 847, 2001 vol. 20, part q.
- Bougnoux P, Dieras V, Petit T, et al. A multicenter phase II study of oxaliplatin as a single agent in platinum and/or taxanes pretreated advanced ovarian cancer: Final results. ASCO Proc 1999; 18: 1422.
- Hansen SW, Tuxen MK, Sessa C. Gemcitabine in the treatment of ovarian cancer. Ann Oncol 1999; 10:S51–S53.
- Peters G, Bergman AM, Ruiz van Haperen WT, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22 (suppl. 4): 72-79.
- Bilgin T, Ozalp S, Yalcin OT, Zorlu G, Vardar MA and Ozerkan K. Efficacy of gemcitabine in heavly pretreated advanced ovarian cancer patients. Eur J Gynaecol Oncol 2003; 24: 169–170.
- Mavroudis D, Kouroussis C, Kakolyris S et al. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. Semin Oncol 2000; 27 (suppl 1):25-30.
- Shibata S, Chow W, Frankel P, et al. A phase I trial of oxaliplatin in combination with gemcitabine: A California Consortium Trial. ASCO Proc 2001; 20: 381, part 1.
- Faivre S, Raymond E, Lokiec F. Final results of the phase I-II and pharmacokinetic study GEM/OX combining gemcitabine with oxaliplatin in patients with advanced non-small cell lung and ovarian carcinoma. ASCO Proc 2001; 20: 2105, part 2.
- Franciosi V, Barbieri R, Vasini G, et al. A feasible com-bination of gemcitabine and oxaliplatin in patients with advanced non small cell lung cancer. Preliminary results of a phase II study. ASCO Proc 2001; 20: 2804, part 2.
- Louvet C, Andre T, Lledo G, et al. Gemcitabine com-bined with oxaliplatin in advanced pancreatic adenocarcino-ma:Final results of a GERCOR Multicenter phase II study. J Clin Oncol, 2002; 20, 6: 1512–1518.
- Macdonald J, Haller D, Mayer R. Grading of toxicity; in Macdonald J, Haller D, Mayer R (eds): Manual of Oncologic Therapeutics. Philadelphia, Lippincott, 1995: 519-523.
- Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.New guidelkines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 3.
- Alberts DS, Dahlberg S, Green SJ et al. Pharmacology of antineoplastic agents in the elderly patient. Cancer 1993; 71: 618–627.
- Thigpen T, Brady MF, Omura GA et al. Age as prog-nostic factor in ovarian carcinoma. Cancer 1993; 71: 606–614.
- Edmonson JH, Su J, Krook JE et al. Treatment of ovarian cancer in elderly women. Cancer 1993; 71: 615–617.
- Markman M, Lewis JL, Saigo P et al. Epithelial ovarian cancer in the elderly. Cancer 1993; 71: 634–637.
- Aravantinos G, Skarlos D, Kosmidis P et al. Irinotecan (CPT-11) in patients with advanced colorectal cancer previous-ly treated with fluorouracil with 5-fluorouracil-based chemotherapy. Crit Rev Oncol Hematol 1999; 32: 209–219.
- Cesano A, Lane SR, Poulin R et al. Stabilization of dis-ease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer patients. Int J Oncol 1999; 15: 1233–1238.
- Raspaglesi F, Zanaboni F, Vecchione F et al. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 2004; 67: 376–381.